Dr. Taylor Doherty

Dr. Taylor A. Doherty is Professor of Medicine and Chief of the Division of Allergy and Immunology. His studies have led to high-impact publications in the fields of asthma, airway remodeling, aspirin-exacerbated respiratory disease (AERD), and group 2 innate lymphoid cell (ILC2) biology.

Research Highlights

• February 2026, study entitled "Sinus mast cell accumulation and persistence suggest a unique endotype in toxin exposure–associated chronic rhinosinusitis" was published in the Journal of Clinical Investigation.
• November 2023, study entitled “Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD” was published in the Journal of Allergy and Clinical Immunology.
• July 2022, study entitled “RNA-binding protein RBM3 intrinsically suppresses lung innate lymphoid cell activation an inflammation partially through CysLT1R” was published in Nature Communications.
• February 2021, study entitle "Cyclic-di-GMP Induces STING-Dependent ILC2 to ILC1 Shift During Innate Type 2 Lung Inflammation" was published in Frontiers in Immunology.
• July 2017, study entitled “Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease” was published in the Journal of Allergy and Clinical Immunology. This article was highlighted in the journal’s Editor’s Choice feature.
• August 2017, study entitled “Leukotriene C4 potentiates IL-33-induced group 2 innate lymphoid cell activation and lung inflammation” was published in the Journal of Immunology.
• July 2013, study entitled “Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production” was published in the Journal of Allergy and Clinical Immunology.
• May 2011, study entitled “The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling” was published in Nature Medicine.